Source: Annual Congress 2001 - Lung cancer treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Zarogoulidis, T. Kontakiotis, P. Hatziapostolou, A. Papagiannis, J. Goutsikas, A. Xafenias, D. Papakosta, D. Patakas (Thessaloniki, Greece). A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer. Eur Respir J 2001; 16: Suppl. 31, 2134

Member's Comments

No comment yet.

Related content which might interest you: The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006 A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 A prospective study on lung toxicity in patients treated with paclitaxel and carboplatin Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 The activity and toxicity of gemcitabine and paclitaxel in previously treated patients with small cell lung cancer (SCLC); preliminary results Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Multicentre phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001 Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002 Combination of erlotinib and bevacizumab in non small cell lung cancer patients Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Effects of treatment with etoposide and cisplatinum in nonsmall cell lung cancer patients-a single institution experience Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003 Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003